{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:09Z","timestamp":1788923889957,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Biologic (b) and targeted synthetic (ts) disease-modifying anti-rheumatic drugs (DMARDs) used in the management of rheumatoid arthritis (RA) target inflammatory pathways implicated in the pathogenesis of multiple myeloma (MM). It is unknown whether use of b\/tsDMARDs affects the incidence of MM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this cohort study using Veterans Health Administration (VHA) data, we identified Veterans newly diagnosed with RA from 1\/1\/2002 to 12\/31\/2018 using diagnostic codes and medication fills. DMARD exposure was categorized as follows: conventional synthetic (cs)DMARDs; bDMARDs, which included tumor necrosis factor inhibitors (TNFi), non-TNFi; and a tsDMARD, tofacitinib. A Cox proportional hazards model with time-varying exposure was used to estimate the hazard ratio for developing MM among those who received b\/tsDMARD medications relative to b\/tsDMARD-na\u00efve persons.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>27,540 veterans with RA met eligibility criteria of whom 8322 (30%) took a b\/tsDMARD during follow-up. There were 77 incident cases of MM over 192,000 person-years of follow-up. The age-adjusted incidence rate (IR) of MM among b\/tsDMARD-na\u00efve patients was 0.37 (95% CI 0.28\u20130.49) per 1000 person-years and 0.42 among current or former b\/tsDMARD users (95% CI 0.25\u20130.65). Adjusting for age and other demographic characteristics, the hazard ratio for MM associated with use of b\/tsDMARDs was 1.32 (95% CI 0.78, 2.26).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In this study of Veterans with RA, the rate of MM did not differ between b\/tsDMARD and csDMARD users. The relatively short duration of follow-up and few events limited our power to detect treatment-related differences in MM risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41927-025-00457-3","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:02:12Z","timestamp":1737082932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis"],"prefix":"10.1186","volume":"9","author":[{"given":"Kate","family":"Tokareva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Baraff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant R.","family":"England","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"1","key":"457_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/24725625.2020.1826651","volume":"5","author":"T Tokunaga","year":"2021","unstructured":"Tokunaga T, et al. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature. Mod Rheumatol Case Rep. 2021;5(1):22\u20138.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"2","key":"457_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0959-8049(93)90188-L","volume":"29a","author":"M Eriksson","year":"1993","unstructured":"Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer. 1993;29a(2):259\u201363.","journal-title":"Eur J Cancer"},{"issue":"1a","key":"457_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/0002-9343(85)90246-3","volume":"78","author":"S Katusic","year":"1985","unstructured":"Katusic S, et al. Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med. 1985;78(1a):50\u20135.","journal-title":"Am J Med"},{"issue":"11","key":"457_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","volume":"31","author":"HA Isom\u00e4ki","year":"1978","unstructured":"Isom\u00e4ki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691\u20136.","journal-title":"J Chronic Dis"},{"issue":"3","key":"457_CR5","doi-asserted-by":"publisher","first-page":"e91461","DOI":"10.1371\/journal.pone.0091461","volume":"9","author":"K Shen","year":"2014","unstructured":"Shen K, et al. Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies. PLoS ONE. 2014;9(3):e91461.","journal-title":"PLoS ONE"},{"issue":"Pt 1","key":"457_CR6","first-page":"1","volume":"374","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1\u201320.","journal-title":"Biochem J"},{"issue":"4","key":"457_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","volume":"11","author":"Q Xiao","year":"2021","unstructured":"Xiao Q, et al. Biological drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021;11(4):941\u201360.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"457_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125\u201339.","journal-title":"Pharmacol Ther"},{"key":"457_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.3389\/fendo.2018.00788","volume":"9","author":"D Harmer","year":"2018","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2018;9:788.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"457_CR10","doi-asserted-by":"publisher","first-page":"155271","DOI":"10.1016\/j.cyto.2020.155271","volume":"136","author":"S Jasrotia","year":"2020","unstructured":"Jasrotia S, et al. Cytokine profile in multiple myeloma. Cytokine. 2020;136:155271.","journal-title":"Cytokine"},{"issue":"33","key":"457_CR11","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20(33):4519\u201327.","journal-title":"Oncogene"},{"issue":"5","key":"457_CR12","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/ijc.32891","volume":"147","author":"GS Calip","year":"2020","unstructured":"Calip GS, et al. Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma. Int J Cancer. 2020;147(5):1300\u20135.","journal-title":"Int J Cancer"},{"key":"457_CR13","doi-asserted-by":"crossref","unstructured":"Wheeler AM, et al. Risk of prostate cancer in US Veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2022.","DOI":"10.1002\/acr.24890"},{"key":"457_CR14","first-page":"1","volume":"2","author":"A Earles","year":"2018","unstructured":"Earles A, et al. Structured Approach for evaluating strategies for Cancer Ascertainment using large-Scale Electronic Health Record Data. JCO Clin Cancer Inf. 2018;2:1\u201312.","journal-title":"JCO Clin Cancer Inf"},{"issue":"5","key":"457_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/pds.5579","volume":"32","author":"J La","year":"2023","unstructured":"La J, et al. Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans affairs Healthcare System. Pharmacoepidemiol Drug Saf. 2023;32(5):558\u201366.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"457_CR16","unstructured":"Team RC. R: a language and environment for statistical computing. 2024. Available from: https:\/\/www.R-project.org\/"},{"issue":"3","key":"457_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/BOR.0000000000000796","volume":"33","author":"N Singh","year":"2021","unstructured":"Singh N, Li CI. Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence. Curr Opin Rheumatol. 2021;33(3):292\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"457_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1093\/rheumatology\/keaa330","volume":"60","author":"K Hellgren","year":"2021","unstructured":"Hellgren K, et al. Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. Rheumatology (Oxford). 2021;60(2):809\u201319.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"457_CR19","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer LK, et al. Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Ann Rheum Dis. 2017;76(12):2025\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"457_CR20","first-page":"2090","volume":"8","author":"Y Sekiguchi","year":"2015","unstructured":"Sekiguchi Y, et al. Epstein-Barr virus-positive multiple myeloma developing after immunosuppressant therapy for rheumatoid arthritis: a case report and review of literature. Int J Clin Exp Pathol. 2015;8(2):2090\u2013102.","journal-title":"Int J Clin Exp Pathol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00457-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T03:02:18Z","timestamp":1737082938000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00457-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00457-3","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by Institutional Review Boards at the University of Washington and the VA Puget Sound in accordance with the Declaration of Helsinki. The consent to participate was waived by Institutional Review Boards at the University of Washington and the R&D committee of the VA Puget Sound.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}